# PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study

> **NCT03837457** · PHASE2 · TERMINATED · sponsor: **miRagen Therapeutics, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Cutaneous T-Cell Lymphoma/Mycosis Fungoides

## Interventions

- **DRUG:** Cobomarsen

## Key facts

- **NCT ID:** NCT03837457
- **Lead sponsor:** miRagen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-01
- **Primary completion:** 2020-07-24
- **Final completion:** 2020-07-27
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Study no longer needed because eligible subjects may receive treatment with cobomarsen in a crossover arm of the SOLAR clinical trial (NCT03713320)
- **Last updated:** 2020-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03837457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03837457, "PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03837457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*